Stephen Welch

Stephen Welch

Auto-generated profile, based on publicly available information

Stephen Welch

London Regional Cancer Program, London, ON, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Annals of Hepato-Biliary-Pancreatic Surgery
Verified
Journal Article
Open access
EWEvelyn Waugh
Evelyn Waugh
JGJuan Glinka
Juan Glinka
DBDaniel Breadner
Daniel Breadner
RLRachel Liu
Rachel Liu
ETEphraim Tang
Ephraim Tang
ASAnton Skaro
Anton Skaro
While patients with borderline resectable pancreatic cancer (BRPC) are a target population for neoadjuvant chemotherapy (NAC), formal guidelines for neoadjuvant therapy are lacking. We assessed the perioperative and oncological outcomes in patients with BRPC undergoing NAC with FOLFIRINOX for patients undergoing upfront surgery (US). The AHPBA criteria for borderline resectability and/or a CA19-9 level > 100 μ/mL defined borderline resectable tumors retrieved from a prospectively populated institutional registry from 2007 to 2020. The primary outcome was overall survival (OS) at 1 and 3 years. A Cox Proportional Hazard model based on intention to treat was used. A receiver-operator characteristics (ROC) curve was constructed to assess the discriminatory capability of the use of CA19-9 > 100 μ/mL to predict resectability and mortality. Forty BRPC patients underwent NAC, while 46 underwent US. The median OS with NAC was 19.8 months (interquartile range [IQR], 10.3-44.24) vs. 10.6 months (IQR, 6.37-17.6) with US. At 1 year, 70% of the NAC group and 41.3% of the US group survived (p = 0.008). At 3 years, 42.5 % of the NAC group and 10.9% of the US group survived (p = 0.001). NAC significantly reduced the hazard of death (adjusted hazard ratio, 0.20; 95% confidence interval, 0.07-0.54; p = 0.001). CA19-9 > 100 μ/mL showed poor discrimination in predicting mortality, but was a moderate predictor of resectability. We found a survival benefit of NAC with FOLFIRINOX for BRPC. Greater pre-treatment of CA19-9 and multivessel involvement on initial imaging were associated with progression of the disease following NAC.

22 August 2024 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
SVSaurav Verma
Saurav Verma
ACAmanda Chapman
Amanda Chapman
LPLee-Anne Pickard
Lee-Anne Pickard
DPDanielle Porplycia
Danielle Porplycia
HMHaley McConkey
Haley McConkey
DBDaniel Breadner
Daniel Breadner
Aim: Human epidermal growth factor receptor-2 (HER2) is a well-established prognostic and predictive biomarker. It is an FDA-approved therapeutic target for HER2 positive breast, gastroesophageal, and more recently, lung and colon cancers. It is an emerging biomarker in biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers. The emergence of new indications warrants further characterization of HER2 expression in diverse cancer populations. This study investigated HER2 expression in solid tumour samples and the feasibility of obtaining these results. Methods: Prospective consent was obtained at a Canadian tertiary academic cancer center from adult oncology patients who were referred for molecular genetic testing of malignant tissue samples. Standard HER2-targeted malignancies were considered breast and gastroesophageal, and were excluded from this study. Between July 2020 and November 2023, 499 samples of solid tumors underwent immunohistochemistry (IHC) HER2 staining. A median turnaround time (TAT) of 14 days would be considered feasible for clinical decision making. Results: The mean age (± SD) of participants was 67 ± 12.5 years, with 270 (54%) male and 229 (46%) female. HER2 protein expression was measured in 42 unique cancer types. IHC levels of 0, 1+, 2+, and 3+ were reported and were 43%, 12%, 35%, and 10% of all analyzable samples respectively (tissue inadequate in 3% of samples). The median TAT for HER2 expression results from time of request to result in release was 18 (interquartile range, 11 to 30) days. Conclusions: HER2 protein expression varies widely between different cancer types. TAT for HER2 IHC results was a median of 18 days, which is close to our feasibility cut-off.

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JDJanet Dancey
Janet Dancey
MKMonika K Krzyzanowska
Monika K Krzyzanowska
DPDiane M. Provencher
Diane M. Provencher
WCWinson Cheung
Winson Cheung
RMRobyn Jane Macfarlane
Robyn Jane Macfarlane
HHHal Hirte
Hal Hirte
2594 Background: Patients (Pts) with rare cancers have few treatment options due to the challenges of conducting clinical trials when projected accrual is low. However, rare cancers may have driver mutations that can be targeted with potentially dramatic therapeutic effects. Methods: IND.206 is a multi-center, non-randomized phase II study of S or T in 11 rare tumor cohorts ( < 100 eligible patients/year in Canada). Cohorts: 8 histologic, 2 genetic, 1 exploratory unspecified. Pts received S (50 mg PO daily x 28 days, q 6 weeks) or T (25 mg IV weekly, q 6 weeks). Each cohort and drug was evaluated separately using a 2 stage design targeting 5 versus 25% RECIST response rate. Blood and tumor were collected for genomic analyses. For trial efficiency, 1) pts could be re-entered to the alternate drug at progression; 2) data collection and SAE reporting were streamlined; 3) cohorts could be stopped early for activity, inactivity or failure to accrue. Central pathology review was performed. Results: The trial wa...

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
ACAnu Chinnadurai
Anu Chinnadurai
DBDaniel Breadner
Daniel Breadner
ZBZiad Baloush
Ziad Baloush
APAna Lohmann Palhares
Ana Lohmann Palhares
MBMorgan Black
Morgan Black
SWStephen Welch
Stephen Welch
Chinnadurai A, et al. J Gynecol Oncol. 2023 Oct;35:e16. https://doi.org/10.3802/jgo.2024.35.e16

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
NDNeesha Dhani
Neesha Dhani
HHHal Hirte
Hal Hirte
MBMarcus Butler
Marcus Butler
SLStephanie Lheureux
Stephanie Lheureux
JBJulie Burnier
Julie Burnier
AOAmit Oza
Amit Oza
5586Background: Cabozantinib is a multi-targeted kinase inhibitor against MET, VEGFR, TIE2, RET, AXL and KIT, influencing mitogenic/angiogenic epithelial-stromal cross-talk. It is a rational strategy in endometrial cancer (EC) where the transient benefit of VEGF-targeting is related to signaling through MET/HGF, TIE2 & AXL. The correlation of MET/HGF with EC pathogenesis also supports evaluating cabozantinib in recurrent/metastatic EC, a poor prognosis disease with no standard 2nd line therapy. Methods: PHL86/NCI#9322/NCT01935934 is a multi-centre, phase II trial of cabozantinib (60mg oral daily on a 28-day cycle) in patients (pts) with EC recurring within a year of adjuvant chemotherapy, or with progression after 1 line of chemotherapy for metastatic disease. Enrollment to experimental (E) cohort is stratified by histology (serous (SER) vs endometroid (END)) in a Simon two-stage design for a co-primary endpoint of response rate ( > 30%) or 12- week progression-free-survival (PFS) ( > 55%). Observation of...

1 February 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
HGHelen Guo
Helen Guo
JBJaclyn Marie Beca
Jaclyn Marie Beca
RRRuby Redmond-Misner
Ruby Redmond-Misner
Wanrudee IsaranuwatchaiWanrudee Isaranuwatchai
Wanrudee Isaranuwatchai
LQLucy Qiao
Lucy Qiao
KCKelvin Chan
Kelvin Chan
375 Background: FFX has been universally publicly funded in Ontario, Canada, for metastatic pancreatic cancer (mPC) and unresectable locally advanced pancreatic cancer (uLAPC) since 11/2011 and 04/2015, respectively. GnP has been publicly funded for uLAPC and mPC (APC) since 04/2015. We examined the real world comparative effectiveness and safety of implementing funding of FFX and GnP for patients with APC. Methods: Patients with APC who received first-line FFX, GnP, or G from 01/2008-03/2016 were identified in CCO’s New Drug Funding Program database and divided into 3 periods: 01/2008-10/2011 (P1), 11/2011-03/2015 (P2), and 04/2015-03/2016 (P3). Data were linked with the Ontario Cancer Registry and others to ascertain demographics, comorbidities, and outcomes. Matching weights of propensity score to simultaneously compare three periods were generated using multinomial logistic regression. Crude and adjusted survival analyses were conducted to assess overall survival (OS) using Kaplan-Meier and weighted Cox regression methods.Weighted negative binomial models were used to estimate rate ratios (RR) for all-cause hospitalization (H) and ED visits. Results: We identified 3696 patients (1250 in P1, 1891 in P2, 555 in P3) (overall mean age 65, female 46%). In P2, 49% received FFX. In P3, 53% received FFX and 35% received GnP. Median OS was 5.7, 7.0, and 7.5 months for P1, P2, and P3, respectively. Median OS for FFX and GnP in mPC were 8.8 and 5.5 months, respectively. OS was improved in P2 vs. P1 (HR = 0.84, 0.78-0.90) and in P3 vs. P2 (HR = 0.82, 0.73-0.92). ED visits were similar compared P2 vs. P1 (RR=1.02, p = 0.75) and P3 vs. P2 (RR=1.04, p = 0.48), and H was reduced in P2 vs. P1 (RR = 0.86, p = 0.01), but similar in P3 vs. P2 (RR = 0.98, p = 0.78). H for febrile neutropenia (FN) was increased in P2 vs. P1 (RR = 2.18, p = 0.04) but not in P3 vs. P2 (RR = 1.32, p = 0.45). Conclusions: Implementation of universal public funding of FFX for mPC improved OS and reduced the rates H overall, but increased FN-related H. Funding of FFX for uLAPC and GnP for APC improved OS without increased in ER and H.